Tenri Institute of Medical Research, Tenri, Japan.
Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Suita, Japan.
Leuk Lymphoma. 2020 Oct;61(10):2389-2398. doi: 10.1080/10428194.2020.1768382. Epub 2020 May 30.
We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10 lymphoma cells ranged widely from 0 to 100%, with a median of 15.7%. Ten patients demonstrated expansion of a single T-cell receptor β-chain repertoire. Lymphoma cells comprised 0.01 to 18.22% (median, 0.26%) of white cells and the absolute numbers ranged from 0.5 to 1491.6 cells (median, 29.3 cells) per microliter of blood. We next found that 14 (70%) and 3 (15%) patients carried and mutations, respectively, in cell-free DNA (cfDNA) in the plasma. The combination of multicolor FCM of the blood, and tests for and hot-spot mutations in plasma cfDNA provides a blood-based 'liquid biopsy' for the diagnosis of AITL.
我们采用两步法多色流式细胞术（FCM）检测 20 例血管免疫母细胞性 T 细胞淋巴瘤（AITL）患者血液中的循环淋巴瘤细胞，所有患者均证实存在肿瘤性 T 细胞。11 例患者 CD3 表达减弱，7 例患者 CD7 丧失表达。CD10 淋巴瘤细胞的比例范围很广，从 0 到 100%，中位数为 15.7%。10 例患者表现为单一 T 细胞受体 β 链谱的扩增。淋巴瘤细胞占白细胞的 0.01%至 18.22%（中位数为 0.26%），每微升血液中的绝对数量为 0.5 至 1491.6 个细胞（中位数为 29.3 个细胞）。我们随后发现，在血浆中的游离 DNA（cfDNA）中，分别有 14 例（70%）和 3 例（15%）患者携带 和 突变。血液多色 FCM 联合检测血浆 cfDNA 中的 和 热点突变，为 AITL 的诊断提供了一种基于血液的“液体活检”方法。
